EHDI Conference March 2, 2010



MEDICAL DIAGNOSES DRIVEN BY UNHS

Cheryl Edwards, AuD Marilyn Neault, PhD Laura Wheaton, ScD



Congenital Cytomegalovirus (CMV) and Hearing Loss Laura Wheaton, ScD, CCC-A



What is Cytomegalovirus (CMV)?

- CMV is a type of herpes virus that often causes an asymptomatic infection in people who are otherwise healthy.
- After becoming infected, the virus remains in the body, dormant for the rest of the person's life.



Types of CMV

- Congenital CMV
 - Infected before birth from either a primary or recurrent maternal infection
- Perinatal CMV
 - Occurring during the periods before, during, or after the time of birth
 - Exposure to infected cervical secretions, breast milk, or blood products



Congenital CMV

- Most common congenital infection
- 40,000 children are born with CMV infection in the US each year.
- Contributes to approximately 400 deaths.
- 8,000 children are diagnosed with permanent disabilities (sensorineural hearing loss, vision impairment, and/or developmental delay).



Treatment

- Currently no cure for CMV.
- Antiviral drugs help with the progression of hearing loss, pneumonia, and retinitis.
- Two drugs commonly used
 - Valganciclovir (intravenous)
 - Ganciclovir (oral)



Children's Hospital Boston Protocol

- Newborn Hearing Screen
 - Unilateral refer
 - Bilateral refer
- Diagnostic ABR
 - Newly identified hearing loss
 - Cheek swab for CMV testing
 - Consultation with Otolaryngology Team
 - Repeat ABR every 4 8 weeks



Case Study (HM)

- Born full term
- Healthy pregnancy and delivery
- Transferred to the NICU at 4 days of life due to petechiae involving head and trunk.



Case Study (HM)


- Thrombocytopenia
- Calcification throughout the brain
- Abdominal ultrasound revealed calcifications of the gallbladder.
- Congenital CMV was diagnosed.



NHS/ABR - First week of life

- Referred bilaterally on the Newborn Hearing Screen (NHS)
- Diagnostic ABR revealed a severe hearing loss bilaterally.
- Absent Distortion Product Otoacoustic Emissions (DPOAEs) bilaterally





Children's Hospital Boston

ABR - 5 weeks of age

- Inpatient evaluation
- Hospitalized for anemia
- Currently taking Ganciclovir
- Parents report no concerns regarding hearing.
- Examination of the ears by an otolaryngologist was performed prior to this appointment.
 - Middle ears were clear.




ABR - 5 weeks of age

Testing Results/Impressions:

- ABR results revealed a moderately-severe hearing loss bilaterally.
- Limited testing as patient woke up
- Improvement in hearing thresholds





Children's Hospital Boston

FREQUENCY IN HERTZ (Hz)

ABR – 9 and 17 weeks of age

- Outpatient visit
- Still taking Ganciclovir; began smaller doses at 17 weeks of age
- Doing well at both visits, per parent report



ABR – 9 and 17 weeks of age

Testing Results:

- ABR results:
 - Right ear: Mild high frequency hearing loss
 - Left ear: Normal hearing
- DPOAE results:
 - Right ear: Present 2K-3K Hz, absent 4K-8K Hz
 - Left ear: Present 2K-8K Hz
- -Normal tympanograms for both ears




ABR – 9 and 17 weeks of age

Testing Impressions:

- 9 weeks: Significant improvement in hearing thresholds in comparison to previous testing
- 17 weeks: Noted stability in hearing sensitivity





Children's Hospital Boston

Future Management

- Audiological follow-up via unsedated ABR testing to monitor hearing sensitivity
- Otologic care per managing otolaryngologist
- Medical management per Infectious Disease (ID) protocol



Conclusion

- Children diagnosed with CMV are at risk for permanent developmental delay and impairments, including hearing loss.
- Early identification of a CMV diagnosis is crucial so that treatment may be prescribed before irreversible damage occurs.
- Hearing loss associated with CMV can improve with appropriate treatment.
- Audiological follow-up is critical.



Questions to Consider

- Should all mothers be tested for CMV?
- Should CMV be a part of newborn screening?
 - Use of the dried blood spot
- Should we develop a universal CMV protocol for all babies who refer on the NHS?
- Need for future research





PROFOUND BILATERAL SENSORINEURAL **HEARING LOSS: IS THAT ALL?** (PART 1) **MARILYN NEAULT, PHD** MARCH 2, 2010

THANK YOU TO MARGARET KENNA, MD, GREG LICAMELI, MD, HEIDI REHM, PHD, AND JENNIFER HARRIS, AUD



Is that all?

- Baby girl born to 19 year old mother, healthy pregnancy, full-term birth
- Mother's half-sibling has mild hearing loss
- Bilateral refer on newborn hearing screen
- Diagnostic ABR → profound bilateral sensorineural hearing loss
- Connexin 26 and connexin 30 negative
- Normal ophthalmology exam at 6 months, recheck recommended



Next chapter

- Parents begin using ASL with baby
- Right cochlear implant surgery at 12 months
- Parents requested test for Usher Syndrome at 17 months because the child was not walking well
- Result: two mutations in the myosin 7A gene (Usher Syndrome Type 1B)



Sister act

- At the time Usher Syndrome was diagnosed, baby sister had just been born
- Baby sister: bilateral refer on NBS, profound bilateral sensorineural hearing loss
- Autosomal recessive inheritance
- Genetic testing showed the same two mutations on the myosin 7A gene as her sister (F1963del and G1942X)
- G1942X is a novel mutation



Parental decisions

- Baby sister also received cochlear implant surgery at 12 months
- Parents considering 2nd implants for both girls
- Both use ASL and are developing spoken language



Usher Syndrome

- Hearing loss at birth
- Vision loss later from retinitis pigmentosa
- 3 6.2 per 100,000 in general population
- 0.6 28% in deaf population
- Still usually late diagnosis
- Limited availability of genetic testing
- Heterogeneous presentation



Usher Syndrome

(3-6% of childhood deafness)

Traditional classification

	Hearing Loss	Vestibular System	Retinitis Pigmentosa
Type I	Congenital profound	Congenital balance problems; absent responses, late walkers (average 20 months)	Onset pre-puberty
Type II	Congenital mild-severe sloping	Normal	Onset in teens-20s
Type III	Progressive later onset	Variable, often progressive balance problems	Variable onset

Children's Hospital Boston

9 genes pinpointed for Usher so far, and there are more

- Type 1 Usher syndrome: MY07A, USH1C, CDH23, PCDH15, SANS
- Type 2 Usher syndrome: USH2A, VLGR1, WHRN
- Type 3 Usher syndrome: USH3A

Testing labs listed at www.genetests.org



Interventions

- Hearing aids
- Cochlear implants
 - Early diagnosis may tip the scales towards CI in families who might not have opted for it in other circumstances
 - Early bilateral CI gives chance for localization
- Physical therapy
- Mobility training
- Vision specialist if vision loss begins early
- Sunglasses, Vitamin A (for Usher Type 2), DHA (fish oil / flax) being studied



Genetic Testing for Usher Syndrome

- Conservative approach
 - HL with retinal abnormalities (positive ERG test, DAT or pigmentary changes)
- Less conservative approach
 - Profound congenital hearing loss with delayed walking
- Even less conservative approach
 - Test infants and children with moderate to profound SNHL if Cx26 (and possibly Cx30) negative
 - Test infants and children with any bilateral SNHL
- No matter which approach, need genetic counseling



Parental needs

- Genetic / medical explanations (available)
- Advice for daily living: when and what to tell the child? how make environment safe? (less available)
- Connections with other parents of young children with Usher (rarely local)

-www.hearseehope.com

 Adult role models with Usher Syndrome and early cochlear implantation (rare)



PROFOUND BILATERAL SENSORINEURAL HEARING LOSS: IS THAT ALL? (PART 2)

> MARILYN NEAULT, PHD MARCH 2, 2010



Baby Boy

- Full term healthy baby, bilateral refer
- Somalian parents, little English, interpreter used for all visits
- Diagnostic ABR at 7 weeks showed profound bilateral sensorineural hearing loss
- Parents: "We accept it. It is from God."



Medical evaluation

- As part of routine workup for profound SNHL, otolaryngologist recommended an electrocardiogram
- Result: markedly prolonged QT interval
- Genetic testing: homozygous deletion in the LQT1 gene
- Diagnosis: Jervell and Lange-Nielsen Syndrome (JLN)
- Incidence 1 / 160,000 to 1 / 600,000
- Autosomal recessive inheritance



Interventions for hearing loss

- Audiogram showed no response to any sound
- Brief trial of loaned hearing aids, no response
- Family Sign Language Program
- Cochlear implant at 2 years 9 months (VERY difficult decision for parents)
- Child is a late walker (>24 months)



Importance of JLN diagnosis

- Long QT in EKG means high risk of fainting and even sudden death
- Caregivers must be aware
- Long QT should be known pre-anesthesia for CI
- Treatment: medication (beta blocker)
- Must avoid QT-prolonging medications
- Cardiologist recommended implanting a defibrillator (parents declined)
- Parents were tested for long QT → mother has it and is now medicated



Take-home messages

- Medical workup and genetic testing are good for more than satisfying curiosity
- Other important conditions can be found apart from the hearing loss
- Other family members may also have the related condition and be unaware





RESULTS OF AN ATYPICAL ABR:

REFER FROM UNHS

CHERYL EDWARDS, AUD MARCH 2, 2010



History

- Born full term, without complication
- Referred in left ear only on AABR screen
- Seen for Dx ABR at 7 weeks of age
- No parental concerns re: hearing
- No family history reported at that time



Results

1000 Hz tympanograms


• Normal bilaterally

Ipsi MEMR

- present 500 Hz 2000 Hz, left
- DNT, right
- DPOAEs
 - Present bilaterally
 - 1500 Hz 8000 Hz, right; 2000 Hz 8000 Hz, left




Right Ear



- Click stimuli at 50 dBnHL and 20 dBnHL
- Click rate decreased from 51.1/sec to 21.1/sec
- Tone Burst ABR elicited Wave V thresholds within normal limits from 1000 Hz – 8000 Hz.



Left Ear



- Wave I with latencyintensity function to 40 dBnHL.
- Comparison of condensation and rarefaction polarities did not yield an abnormal CM



Follow-up

- Referred to Otolaryngology; imaging deferred until after second ABR
- Testing at 3 months:
 - Tympanograms: Normal
 - Ipsi MEMR: present, right; absent, left
 - ABR: Same responses, morphology worse
 Slowed rate to 11.1/sec in the left ear
- Otolaryngology: recommended MRI



MRI – 3 months

SIGNA EXCITE SYS#MRS2000 Acc Num: 10160345 Ex: 17843 SE: 4 F 3 MONTH 41 11641 8 FSE T2 1 NEX (Brsin) DOB: 2/17/2005 5/25/2006 IM: 7 8: -24,8 BW: 81.37 10:27:41 AM SE TR: 3800 ETL: 8 TE: 100.30 EC: 1 Coil: SHRBRAIN SP: 5 Acg Time: 10:27:41 AM **THK: 4** Z: 1.75 W: 1523 C: 833 FA: 90 **NEX: 1** DFOV: 11.4x11.4cm ScanOpt: FC_SLICE_AX_GEMS\FC\SAT_GEMS\FILTERED_GEMS\SP AQM:256\384 Ctr: 0 0 0 Page: 7 of 23 DIM: 0 0 0 I CM

0.6 cm x 0.6 cm x 0.9 cm




Radiology/Neurosurgery

- Unknown if mass is a tumor or vascular malformation (hemangioma)
- Felt that left ABR is affected due to involvement of the cerebellar peduncle
- Due to location, biopsy was deferred and monitoring via MRI recommended



MRI – 22 months





Biopsy completed at 12 months

- Low grade pilocytic astrocytoma
 - Extends into cerebellum, dorsal pons and lower medulla
- Chemotherapy initiated at 14 months
 - Vincristine and carboplatin
- Mass has remained stable at 2.6 x 2.0 cm



Status: age 2 years

- Hearing
 - Evaluated every 3 months
 - Normal in sound field
 - SAT of 40 dB HL in the left ear
 - Not a big fan of the headphones
- Social and engaging
- 200 words, can sing ABCs
- OT/PT every 2 weeks
- Mobility increased, gait "unstable"
- Intermittent nystagmus, eye crossing
 - Using glasses



Conclusions

- What if OAEs had been used for screening ...or follow-up
- Close collaboration with ORL, Genetics, Neurology, Neurosurgery, Ophthalmology, Radiology



Thank you!



